P reeclampsia is a pregnancy-related disorder, clinically characterized by the new onset of proteinuria and hypertension in the second half of pregnancy, with a great effect on maternal and fetal morbidity and mortality worldwide. 1 A better understanding of the pathogenic mechanisms underlying preeclampsia might help identifying biomarkers that allow early diagnosis and treatment of preeclampsia. Recently, disturbances in angiogenic balance (favoring antiangiogenic over proangiogenic factors), elevated endothelin-1 (ET-1) levels, and a suppressed renin-angiotensin-aldosterone system (RAAS) have been reported. [2][3][4] As a consequence, the ratio of the antiangiogenic soluble Fms-like tyrosine kinase-1 (sFlt-1) and the proangiogenic placental growth factor (PlGF) is now thought to be a reliable biomarker for the diagnosis of preeclampsia. 5 In fact, patients with a ratio ≥85 have a poor pregnancy outcome independent of their clinical diagnosis compared with patients with a ratio <85. 5 Of interest, treatment of cancer patients with antiangiogenic drugs (which, like sFlt-1, prevent the actions of vascular endothelial growth factor [VEGF]) resulted in hypertension, proteinuria, renin suppression, and elevated ET-1 levels. 6 Animal studies with antiangiogenic drugs additionally revealed that the renal histological changes observed during such treatment, in particular glomerular endotheliosis, resembled the renal alterations observed in preeclampsia. 7 From the observation that the dual ET A/B receptor antagonist macitentan prevented both the rise in blood pressure and proteinuria during Abstract-Women with preeclampsia display low renin-angiotensin-aldosterone system activity and a high antiangiogenic state, the latter characterized by high levels of soluble Fms-like tyrosine kinase (sFlt)-1 and reduced placental growth factor levels. To investigate whether renin-angiotensin-aldosterone system suppression in preeclampsia is because of this disturbed angiogenic balance, we measured mean arterial pressure, creatinine, endothelin-1 (ET-1), and reninangiotensin-aldosterone system components in pregnant women with a high (≥85; n=38) or low (<85; n=65) soluble Fms-like tyrosine kinase-1/placental growth factor ratio. Plasma ET-1 levels were increased in women with a high ratio, whereas their plasma renin activity and plasma concentrations of renin, angiotensinogen, and aldosterone were decreased. Plasma renin activity-aldosterone relationships were identical in both the groups. Multiple regression analysis revealed that plasma renin concentration correlated independently with mean arterial pressure and plasma ET-1. Plasma ET-1 correlated positively with soluble Fms-like tyrosine kinase-1 and negatively with plasma renin concentration, and urinary protein correlated with plasma ET-1 and mean arterial pressure. Despite the lower plasma levels of renin and angiotensinogen in the high-ratio group, their urinary levels of these components were elevated. Correction for albumin revealed that this was because of increased glomerular filtration. Subcutaneous arteries obtained from patients with preeclampsia displayed an enhanced, AT 2 receptor-mediated response to angiotensin II. In conclusion, a high antiangiogenic state associates with ET-1 activation, which together with the increased mean arterial pressure may underlie the parallel reductions in renin and aldosterone in preeclampsia. Because ET-1 also was a major determinant of urinary protein, our data reveal a key role for ET-1 in the pathogenesis of preeclampsia. Finally, the enhanced angiotensin responsiveness in preeclampsia involves constrictor AT 2 receptors. (Hypertension. 2015;65:1316-1323. The online-only Data Supplement is available with this article at http://hyper.ahajournals.org/lookup/suppl/
antiangiogenic treatment, it seemed that ET-1 is causally involved in these preeclampsia-like side effects. 8 A suppressed RAAS in preeclampsia is counterintuitive given the reduced circulating volume in this disorder. 2, 9 Gennari-Moser et al 10 have proposed that VEGF stimulates aldosterone production, both directly and indirectly, the latter by enhancing adrenal capillary density. On this basis, a rise in sFlt-1, via VEGF inactivation, should suppress aldosterone levels in preeclampsia. Buhl et al 11 observed that urinary plasmin levels are elevated in preeclampsia. The resulting epithelial sodium channel activation might also suppress aldosterone. Finally, the occurrence of angiotensin II (Ang II) type 1 (AT 1 ) receptor autoantibodies in preeclampsia, which stimulate the AT 1 receptor, should suppress renin (negative feedback loop) but increase aldosterone. Their presence may contribute to the high Ang II sensitivity in preeclampsia. Careful analysis of the plasma aldosterone/plasma renin concentration (PRC) ratio in preeclampsia might shed light on these possibilities. In the past, this ratio has been shown to be elevated in pregnant women, the highest ratio in fact occurring in preeclampsia. 4 However, given the substantial angiotensinogen rises in pregnancy (and to a lesser degree in preeclampsia), Ang I generation for a given level of renin may differ greatly between pregnant and nonpregnant women. Therefore, the plasma aldosterone/plasma renin activity (PRA) ratio might be more appropriate to investigate this relationship. Given the renal damage in preeclampsia, urinary RAAS component measurement could provide additional diagnostic information, provided that such components are truly kidney-derived (and not plasma-derived). 12 In this study, we hypothesized that RAAS suppression in preeclampsia is the consequence of the disturbed angiogenic balance or the resulting rise in ET-1, and that urinary RAAS components provide additional diagnostic information, for example, on the degree of renal dysfunction. To address these hypotheses, we measured sFlt-1, PlGF, ET-1, and RAAS components in plasma and urine of pregnant women with sFlt-1/ PlGF ratios ≥85 or <85. We additionally investigated what Ang II receptor (type 1 or type 2) contributes to the enhanced Ang II responsiveness in preeclampsia, making use of subcutaneous arteries obtained after caesarean delivery.
Methods
Methods are available in the online-only Data Supplement.
Results

Rat Studies
An 8-day treatment with the VEGF inhibitor sunitinib dosedependently increased plasma ET-1 levels in Wistar Kyoto rats ( Figure 1A ).
Human Studies
Population Characteristics
Of the 103 pregnant women included, 65 had a sFlt-1/PlGF ratio <85 (negative test) and 38 had a ratio ≥85 (positive test). There were no differences in gestational age at inclusion. Patients with a positive test had a higher blood pressure and delivered on average 8 weeks earlier than patients with a negative test. As expected, treatment with methyldopa, calcium antagonists, and magnesium sulfate predominated in the group with the positive test (Table 1) . Plasma ET-1 and creatinine levels were increased in patients with a positive test, whereas PRA, PRC, and plasma angiotensinogen, aldosterone and albumin were decreased in these patients (Table 1) . Plasma ET-1 correlated positively with plasma sFlt-1 ( Figure 1B ). Plasma prorenin, the aldosterone/PRA ratio, and the PRA-aldosterone relationship were identical in both the groups (Table 1 ; Figure 2A ).
Urinary protein, albumin, angiotensinogen, renin, and prorenin were increased in patients with a positive test, whereas aldosterone was decreased in the urine of such patients ( Table 2) . Urinary Na + levels were identical in both the groups, also after correction for K + . For the analysis of prorenin differences, samples that yielded levels below the detection limit (11 [31.4%] in the women with a positive test and 33 [54.1%] in women with a negative test) were excluded. There was no difference in urinary creatinine levels between the 2 groups, and outcomes were identical with and without correction for creatinine. Angiotensinogen measurements by enzyme-kinetic assay and ELISA were significantly correlated ( Figure 2B ; r=0.33; P<0.001), although levels determined with the ELISA were consistently 2-to 3-fold lower. This was most probable because of the fact that the ELISA standard, when determined twice in our enzyme-kinetic assay (applying Ang I as standard), yielded ≈2-fold higher levels than predicted (0.37 versus 0.15 pmol/mL and 1.03 versus 0.62 pmol/mL).
Determinants of Plasma Aldosterone, PRC, Plasma ET-1, MAP, and Urinary Protein/Creatinine Ratio
Aldosterone
Plasma sFlt-1, mean arterial pressure (MAP), urinary protein/creatinine ratio (uPCR), and plasma ET-1 correlated negatively with plasma aldosterone, whereas a positive correlation was observed with plasma PlGF, gestational age at measurement, plasma angiotensinogen, PRC, and PRA (Table  S1 ). Next, parameters displaying a significant correlation with plasma aldosterone were added into a multiple linear regression model (using PRA as a representative of both PRC and angiotensinogen, and deleting uPCR in view of its strong relationship with MAP). Under such conditions, only gestational age at measurement and PRA remained significant determinants (Table S2 ). Replacing PRA in the model by PRC and plasma angiotensinogen revealed that the association with PRA was because of PRC (P=0.006) and not plasma angiotensinogen (P=0.649; data not shown). Ang indicates Angiotensin; DBP, diastolic blood pressure; G.A., gestational age; MAP, mean arterial pressure; PlGF, placental growth factor; PRA, plasma renin activity; SBP, diastolic blood pressure; and sFlt, soluble Fms-like tyrosine kinase. 
Plasma Renin Concentration
PRC correlated positively with PRA, plasma PlGF, plasma angiotensinogen, and plasma aldosterone, and negatively with plasma sFlt-1, MAP, uPCR, and plasma ET-1 (Table S1 ). There was no relationship with gestational age at measurement. When incorporating all significant parameters into a multiple regression model (excluding uPCR like above), only MAP and plasma ET-1 remained significantly correlated with PRC (Table S3 ). Aldosterone was kept out of this analysis because of its well-known strong positive correlation with renin, mediated by renin-induced angiotensin generation.
Endothelin-1
Plasma ET-1 correlated positively with plasma sFlt-1, creatinine, MAP, and uPCR, and negatively with plasma PlGF, PRC, PRA, plasma angiotensinogen, and plasma aldosterone (Table  S1 ). There was no relationship with gestational age at measurement. Adding all independent significant parameters in a multiple linear regression model revealed that only the relationships with sFlt-1 and PRC remained significant (Table S4 ).
MAP and uPCR
MAP and uPCR correlated highly significantly with each other, and displayed identical positive correlations with plasma sFlt-1 and plasma ET-1, and negative correlations with PRA, plasma angiotensinogen, and plasma PlGF. In addition, uPCR correlated positively with plasma creatinine, and negatively with PRC and plasma aldosterone. Multiple linear regression analysis revealed that only plasma PlGF and uPCR correlated independently with MAP (Table S5) , whereas plasma PlGF, plasma ET-1, and MAP determined 69% of uPCR variation (Table S5 ).
Origin of Urinary RAAS Components
At first sight, the opposite changes in urinary renin and angiotensinogen in urine versus plasma in the 2 groups (Tables 1 and 2) seem to indicate a differential regulation of the circulating and renal RAAS. However, these data should be interpreted in view of the increased albumin/protein levels in the urine of patients with a high ratio. Figures 3A-3C , therefore, compare the plasma/urine ratio of albumin with the ratios of renin, prorenin, and angiotensinogen. The highly significant positive relationships with the albumin ratio for the 3 proteins, which all have a molecular mass that is comparable to that of albumin, strongly suggest that their elevated urinary levels simply reflect the same phenomenon that underlies the elevated urinary albumin/protein levels: increased filtration. To establish the relationship for prorenin, we excluded urinary samples that yielded levels below the detection limit (n=44). Urinary aldosterone changes paralleled plasma aldosterone changes, and both parameters were highly correlated ( Figure 3D ). Here, we did not correct for albumin, given the much lower molecular weight of aldosterone. Urinary aldosterone levels for a given level of urinary sodium (corrected for potassium, a measure for the aldosterone effect on the collecting duct) were lower for women with a positive test ( Figure 4 ).
Microvascular Function
Ang II CRCs were obtained in subcutaneous arteries from 9 patients with preeclampsia (age, 31±4 years; gestational age, 29±3.5 weeks; MAP, 111±7 mm Hg) and 8 healthy controls (age, 35±5 years; gestational age, 39±0.5 weeks; MAP, 81±8 mm Hg; P<0.05 versus preeclampsia for all). Maximum constrictor responses to KCl and relaxant effects to substance P were identical in both the groups (data not shown). As expected, the Ang II E max was twice as large in preeclampsia vessels as compared with healthy vessels ( Figure S1 ), whereas Ang II potencies in both the vessel types were identical (pEC 50 , 8.9±0.15 versus 9.0±0.13). Irbesartan completely abolished all Ang II responses (data not shown), whereas PD123319 normalized the enhanced response in preeclampsia (P<0.05), without having an effect in healthy vessels ( Figure S1 ).
Discussion
In this study, we have used a cut-off of 85 of the sFlt-1/PlGF ratio to distinguish patients with a high and low antiangiogenic state, rather than making a subdivision based on the clinical diagnosis of preeclampsia. This was done mainly in view of our purpose to investigate the relation between the antiangiogenic state, the endothelin system, and the RAAS. It also minimizes the risk of including patients with preexisting disease such as systemic lupus erythematosus. 13 However, it should be noted here that a reanalysis on the basis of a subdivision according clinical diagnosis yielded identical results (data not shown).
A high antiangiogenic state, as reflected by elevated sFlt-1 levels, is associated with increased ET-1 levels. Given the observation that ET-1 also rises in patients with cancer and rats treated with the VEGF inhibitor sunitinib ( Figure 1A ), 6 the most logical explanation of this ET-1 rise is that it is the direct consequence of VEGF inhibition, either through VEGF inactivation by sFlt-1 (in preeclampsia) or through interference with VEGF signaling (with sunitinib). Elevated ET-1 levels have been reported earlier in preeclampsia. 14, 15 Our study now suggests that this ET-1 elevation is a major determinant of both the blood pressure rise and the proteinuria in this disorder, as well as the RAAS suppression ( Figure 5 ). Again a parallel may be drawn with the ET-1-mediated side effects in sunitinib-treated patients, that is, hypertension and proteinuria, which were accompanied by renin suppression. 6 ET receptor blockade prevented these side effects in sunitinib-treated rats, 8 whereas also in 2 rat models for preeclampsia (reduced uterine perfusion pressure and sFlt-1 injection) ET receptor antagonism completely blocked the hypertensive response. 16, 17 Moreover, ET-1 has been reported to suppress renin release in animal models. 18, 19 The cause of the RAAS suppression in preeclampsia has always been elusive. Given the reduced circulating volume in preeclampsia, the opposite should have occurred. 2 Apparently, both the ET-1 and the rise in blood pressure overrule this response. Importantly, our data show a similar PRA-aldosterone relationship and aldosterone/PRA ratio in patients with a high and low antiangiogenic state. This implies that the decrease in aldosterone levels in preeclampsia is the simple consequence of reduced Ang I-generating activity. Gennari-Moser et al 10 have recently reported that VEGF stimulates aldosterone production by enhancing adrenal capillary density. In addition, they observed that sFlt-1 overexpression in rats reduced aldosterone levels, resulting in an inverse correlation between sFlt-1 and aldosterone. Our data fully confirm this inverse relation in humans, but multiple regression analysis subsequently revealed that it was actually because of the sFlt-1-induced rise in ET-1, which suppressed renin. Moreover, had aldosterone been selectively reduced in preeclampsia, this should have resulted in a reduced aldosterone/PRA ratio. No such reduction was observed. In fact, if anything, previous studies reported an elevated aldosterone/PRC ratio in preeclampsia versus healthy pregnant women. 4 Here, it should be considered that pregnant women display elevated prorenin and angiotensinogen levels. 2 Prorenin may interfere in the immunoreactive renin assay by cross-reacting with the antibody that recognizes renin's active site, 20 and the 4-to 5-fold elevated angiotensinogen levels will lead to a higher PRA (and, consequently, aldosterone) level for a given PRC as compared with nonpregnant women. From this point of view, it is better to compare aldosterone with PRA because this parameter takes into account the changes in angiotensinogen and is not affected by prorenin cross-reactivity. Summarizing, our data do not support a selective, reninindependent downregulation of aldosterone in preeclampsia (related to a reduced adrenal capillary density) but rather an ET-1-mediated overall RAAS suppression ( Figure 5 ).
Buhl et al 11 found that urine of patients with preeclampsia contains high levels of plasmin, which will activate collecting duct epithelial sodium channel current, and might thus further suppress the RAAS. Because plasma sodium is kept within narrow ranges and urinary sodium is largely diet-dependent, it is difficult to obtain direct evidence for this theory in an observational study. However, in line with the theory that sodium could be retained by activation of epithelial sodium channel, we observed that urinary sodium levels for a given level of aldosterone were lower in patients with a high antiangiogenic state as compared with healthy pregnant women.
Because RAAS components in urine are thought to reflect renal RAAS activation, 21, 22 and given the severe renal pathology in preeclampsia, we quantified urinary renin, prorenin, angiotensinogen, and aldosterone to investigate their biomarker value. In line with previous studies, urinary prorenin levels were often below detection limit. 23, 24 When considering only the urinary prorenin levels that were detectable, it could be calculated that urinary prorenin levels were 0.21 (0.12-0.45) and 0.51 (0.19-1.47) % (P=0.007 for difference) of plasma prorenin in women with a low and high antiangiogenic state, respectively (Figure 3) . In reality, when also including the samples with undetectable prorenin levels, these percentages would have been even lower, and possible as low as those observed for angiotensinogen (0.07 [0.03-0.11] and 0.16 [0.05-0.34] % of plasma angiotensinogen; P=0.001). In contrast, urinary renin levels, relative to PRC, were ≤90-fold sFlt-1 binds free placental growth factor (PlGF) and vascular endothelial growth factor (VEGF), thereby inactivating these factors, increasing the sFlt-1/PlGF ratio, and inducing endothelial dysfunction. As a consequence, endothelin-1 production is turned on, which not only induces hypertension and proteinuria but also suppresses renin release. Such suppression will also occur because of the rise in blood pressure. The renin suppression is accompanied by a parallel aldosterone suppression, illustrating that the latter is entirely because of diminished angiotensin generation. Diminished renin-angiotensin-aldosterone system activity combined with high blood pressure results in a reduced circulating volume, thereby further decreasing placental perfusion. P<0.001). Because of the comparable molecular weights of all 3 proteins, at first sight these data seem to indicate selective renal renin release into urine, particularly in women with a high antiangiogenic state. However, when comparing the urine/plasma ratios of all the 3 proteins with the ratio of a protein of comparable weight, albumin (displaying urinary levels that are 0.014 [0.005-0.033] and 1.35 [0. .40] % of plasma albumin in women with a low and high antiangiogenic state, respectively; P<0.007), strong correlations were found in all cases. In other words, renin, prorenin, and angiotensinogen enter urine, like albumin, via glomerular filtration, and their elevated levels in women with a high antiangiogenic state are the simple consequence of increased filtration. This leaves the question why urinary renin (relative to its plasma levels) is so much higher than urinary angiotensinogen or prorenin. Urinary renin levels are too low to significantly affect urinary angiotensinogen, and thus ex vivo Ang I generation cannot explain the low urinary angiotensinogen levels. Clearly, therefore, either glomerular filtration of prorenin and angiotensinogen is greatly reduced as compared with renin, or renin reabsorption in the proximal tubulus is much less efficient. Because Nielsen et al 25 found that, after blocking tubular reabsorption with lysine, the urinary clearance of prorenin was still ≈10-fold lower than that of renin, the former explanation seems the most likely. Finally, urinary aldosterone fully paralleled plasma aldosterone, in line with the concept that urinary aldosterone, like plasma aldosterone, is adrenal-derived. Thus, except for the fact that urinary aldosterone is several orders of magnitude higher than plasma aldosterone (making it easier to detect), urinary aldosterone offers no additive biomarker value for preeclampsia, nor do urinary angiotensinogen, renin, and prorenin.
Women with preeclampsia are known to display greater Ang II responses than normal pregnant women. Theoretically, such enhanced responses should result in higher aldosterone levels and a reduced renin release, via AT 1 receptors in the adrenal and kidney, respectively. Collectively, this would lead to an higher aldosterone/PRA ratio. Yet, we did not observe an altered ratio, arguing against the concept of enhanced AT 1 receptor stimulation in preeclampsia. Our data in arteries from patients with preeclampsia confirm the enhanced response, but show that it is because of constrictor AT 2 receptors. Normally, such receptors induce vasodilation, but their phenotype often changes under pathological conditions, such as hypertension and aging. 26, 27 The mechanism behind this change from dilator to constrictor is unknown, but may involve a disturbed endothelial function and reduced NO availability, heterodimerization with other receptors (including the AT 1 receptor) or a different location of the AT 2 receptor (vascular smooth muscle cells versus endothelial cells). 28 If the enhanced response is indeed because of AT 2 receptors, this explains why there is no change in the aldosterone/PRA ratio.
Perspectives
Our data shed new light on the counterintuitive RAAS suppression in preeclampsia, and suggest that ET-1 has a key role not only in the pathogenesis of this disorder (contributing both to the high blood pressure and proteinuria) but also as a renin suppressor. The reduced urinary sodium/aldosterone relationship in women with a high antiangiogenic state support a second reason for RAAS suppression: the occurrence of plasmin in urine, which selectively activates epithelial sodium channel. 11 We did not find evidence for specifically reduced aldosterone levels in patients with an antiangiogenic state. Urinary RAAS components, when corrected for albumin, fully reflected the alterations in the circulating RAAS in preeclampsia, and thus offered no additive value as biomarkers. Unfortunately, despite the central role for ET-1 in preeclampsia, ET receptor antagonism currently is no treatment option in human pregnancy because of its teratogenic effects. 29 To develop treatment modalities for preeclampsia beyond ET receptor blockade, future studies should unravel why elevated sFlt-1 levels in preeclampsia, like VEGF inhibition in patients with cancer, increase ET-1 levels. Such studies might involve animal models of preeclampsia using VEGF antagonism, and should take into consideration that ET-1 has been reported to reciprocally affect the expression of VEGF and its receptors. 30, 31 
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